Lamictal XR is approved as an add-on therapy for adult and adolescent patients who experience partial seizures with or without secondary generalization.
Lamictal XR reduced the frequency of partial seizures during a 19-week study. More patients who took Lamictal XR had a significant reduction in seizure frequency, as compared to placebo.
Dean Naritoku, Professor and Chairman of neurology, said: Many patients require multiple doses of one or more medications to control their epilepsy, which makes taking their medicines even more challenging.”
“Lamictal XR is an important once-daily advance for patients with epilepsy who still experience seizures while taking their current therapy, he added.